Diagnostic and therapeutic value of progastrin‐releasing peptide on small‐cell lung cancer: A Single‐Center Experience in China. Issue 9 (10th July 2018)

• Record Type: Journal Article
• Authors: Wu, Xiao‐Yuan; Hu, Yang‐Bo; Li, Hui‐Juan; Wan, Bing; Zhang, Chen‐Xi; Zhang, Bin; Hu, Huan; Zhang, Qun; Lv, Tang‐Feng; Zhan, Ping; Song, Yong
• Is Part Of: Journal of cellular and molecular medicine. Volume 22:Issue 9(2018)
• Page Start: 4328
• Page End: 4334
• Publication Date: 2018-07-10
• Subjects: diagnosis -- neuron‐specific enolase -- progastrin‐releasing peptide -- small‐cell lung cancer -- therapeutic monitoring; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.13722
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: We aimed to compare the diagnostic efficiency of proGRP and NSE on SCLC and to investigate whether the change of proGRP level would predict therapeutic response. Patients who were firstly diagnosed pathologically in Nanjing Chest Hospital and measured proGRP level consecutively were enrolled in the study. ProGRP level was detected using Elecsys ProGRP Assay. Totally 75 SCLC, 234 NSCLC and 264 benign lung diseases (BLD) were enrolled. Both proGRP and NSE levels in SCLC were significantly higher than those in NSCLC and BLD, and proGRP in extensive stage SCLC was higher than which in limited stage ( P ≤ .001). The diagnostic efficiency of proGRP on SCLC was higher than that of NSE, but when the two biomarkers were bind together, the diagnostic efficiency was the best. When SCLC was differentiated from NSCLC and BLD, the cut‐off values were 114.35 pg/mL and 162.55 pg/mL respectively. For treatment responsive patients, proGRP level decreased markedly after the first cycle of therapy and kept a continued momentum of decline during treatment. But for unresponsive patients, no obvious decline was observed. ProGRP had higher diagnostic efficiency on SCLC when compared to NSE, and it could better predict therapeutic response of pulmonary target lesions on chemotherapy.